November 7, 2018 / 8:02 AM / 10 days ago

Drug maker Lundbeck raises 2018 financial guidance

Nov 7 (Reuters) - Danish drug maker Lundbeck raised its full-year financial guidance on Wednesday citing “better-than-expected sales performance”.

Lundbeck raised its full year EBIT forecast to 5.1-5.4 billion Danish crowns from 4.9-5.2 billion crowns.

The company, which develops drugs for brain disorders, delivered a third-quarter operating profit of 4.45 billion Danish crowns versus the 4.44 billion forecasts by analysts in a Reuters poll.

Lundbeck is expecting to see growth for 2018 in all regions although a significant decline in Onfi sales is expected from the fourth quarter onwards. (Reporting by Izabela Niemiec in Gdynia; editing by Jason Neely)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below